Amylyx Pharmaceuticals, Inc. AMLX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s change in accrued liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported change in accrued liabilities of -$6.67M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s change in accrued liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s change in accrued liabilities increased by 43.8% year-over-year, from -$11.88M to -$6.67M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.